SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

MNKD

MannKind
BEARISH
Impact 5/10
Horizonweeks Processed11d 5h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Monitor Q4 2026 for Furoscix revenue trajectory, as management expects Q4 Furoscix revenue to exceed the first half of 2026 combined. Watch for updates on the global Phase 2 INFLO-2 trial for MNKD-201 and the $15M milestone payments from United Therapeutics anticipated in 2027.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

MNKD drug pipeline →

nintedanib DPI

▲ Bullish Named in this press release
Impact
Phase
Phase 2 (enrolling)
Time to market
At least 3-5 years away, assuming successful Phase 2 and Phase 3 trials and subsequent regulatory filings
Next catalyst
None dated

What to watchWatch for Phase 2 INFLO-2 enrollment completion updates and eventual topline efficacy data (likely 12-18 months out). For MNKD overall, the approved Afrezza and Furoscix franchises are nearer-term value drivers; nintedanib DPI is a pipeline optionality play. MannKind's analyst consensus is Strong Buy (12 Buy/Strong Buy vs 2 Hold) with a mean price target of $7.97 (84% upside from ~$4.07), but the stock also shows elevated short-volume ratios, indicating debate.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$3.90
T+0 close · Nov 5, 2026 · via day close
Latest settled
+5.90%
T+5 · $4.13
Vs SPY
+3.30%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $3.90entry
  2. T+1 · 8d ago +7.44%α +5.07% · $4.19
  3. T+5 · 4d ago +5.90%α +3.30% · $4.13
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MannKind reported Q3 2026 total revenue of $101.9M (+24% YoY), slightly below the $108.5M consensus, and GAAP EPS of -$0.07 vs consensus -$0.01. Furoscix revenue of $22.4M and the rapid adoption of Furoscix ReadyFlow (75% of shipments by late October) were highlights, but higher SG&A costs (up 111% YoY) drove a net loss of $23.2M vs a year-ago profit of $8.0M.

Key Financial Metrics

EPS
−$0.07
est −$0.01 · -600.0%
Revenue
$101.9M
est $108.5M · -6.1% · +24.0% YoY
Rating
miss

Key Facts

  • Q3 2026 total revenue $101.9M, +24% YoY, below $108.5M consensus
  • GAAP EPS -$0.07 vs consensus -$0.01 (miss)
  • Non-GAAP adjusted net loss $3.6M, or -$0.01 per share
  • Furoscix revenue $22.4M; Furoscix ReadyFlow launched mid-September, 75% of shipments by late October
  • Afrezza revenue $19.3M, +5% YoY; pediatric launch driving 80% increase in new-to-brand prescriptions QoQ
  • SG&A expenses $61.4M, +111% YoY, driven by Furoscix launch and pediatric Afrezza promotion
  • Cash and investments $96.6M; closed $50M private placement in July 2026
  • Positive Phase 1b INFLO-1 results for nintedanib DPI (MNKD-201); global Phase 2 underway

Financial Impact

Revenue miss of ~$6.6M vs consensus; net loss of $23.2M vs year-ago profit of $8.0M; SG&A more than doubled to $61.4M

revenueepsoperating expensesnet income

Segment Breakdown

SegmentRevenueGrowth
Afrezza$19.3M+5.0%
Furoscix$22.4MNot reported
V-Go$3.3M-14.0%
Collaborations and services$19.4M-27.0%
Royalties$37.5M+12.0%

Risk Factors

  • Revenue missed consensus by ~6%, driven by lower collaboration revenue from UT
  • SG&A expenses surged 111% YoY, pressuring profitability
  • Net loss of $23.2M vs year-ago profit of $8.0M; cash burn may require additional financing
  • Furoscix gross margin is lower than Afrezza, weighing on overall margins
  • Dependence on United Therapeutics for royalty revenue and collaboration income

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397002

Track record

17 reports on MNKD

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  3. Nov 5, 202611d ago Press Release Bearish 5/10 Viewing Entry $3.90 Now $3.96 −1.54% settles Dec 7
  4. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
  5. Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
  6. Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
  7. Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
  8. Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
  9. Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
  10. May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026